Brett T. Staahl

Prior to the founding of Scribe Therapeutics Brett Staahl worked as a Postdoctoral Fellow in the Doudna Lab at UC Berkeley on the research of CRISPRCRISPR ribonucleoproteins, developing precise in vivo and ex vivo protein-to-cell delivery methods for the safe inactivation of disease-causing genes and slowing of neurodegeneration.

Prior to the founding of Scribe Therapeutics Brett Staahl worked as a Postdoctoral Fellow in the Doudna Lab at UC BerkeleyUC Berkeley on the research of CRISPR ribonucleoproteins, developing precise in vivo and ex vivo protein-to-cell delivery methods for the safe inactivation of disease-causing genes and slowing of neurodegeneration.

Prior to the founding of Scribe Therapeutics Brett Staahl worked as a Postdoctoral Fellow in the Doudna LabDoudna Lab at UC Berkeley on the research of CRISPR ribonucleoproteins, developing precise in vivo and ex vivo protein-to-cell delivery methods for the safe inactivation of disease-causing genes and slowing of neurodegeneration.

Prior to the founding of Scribe Therapeutics Brett Staahl worked as a Postdoctoral Fellow in the Doudna Lab at UC Berkeley on the research of CRISPR ribonucleoproteins, developing precise in vivo and ex vivo protein-to-cell delivery methods for the safe inactivation of disease-causing genes and slowing of neurodegeneration.